NEW YORK, April 19 (GenomeWeb News) - General Electric, through its Global Research and GE Healthcare units, has inked a research collaboration with Eli Lilly for the discovery of diagnostics and therapeutics for Alzheimer's disease, the companies said today.
According to the companies, the research collaboration will target beta-amyloid protein.
GE Healthcare will have access to Lilly's molecular libraries to search for compounds that might be used in targeted diagnostic imaging agents for Alzheimer's.
Lilly will subsequently have access to any diagnostic agents developed by GE to use in the discovery of Alzheimer's therapeutics, the companies said.